Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Chemotherapy for Stem Cell Mobilization in Non-Hodgkin's Lymphoma
NCT01329900Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2011
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Mobilization Rate at Day 21. Started Aug 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01329900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01329900.